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Abstract
Acute lung injury (ALI) is a clinical manifestation of respiratory failure, caused by lung inflammation and the disruption of
the alveolar-capillary barrier. Preservation of the physical integrity of the alveolar epithelial monolayer is of critical
importance to prevent alveolar edema. Barrier integrity depends largely on the balance between physical forces on cell-cell
and cell-matrix contacts, and this balance might be affected by alterations in the coagulation cascade in patients with ALI.
We aimed to study the effects of activated protein C (APC) on mechanical tension and barrier integrity in human alveolar
epithelial cells (A549) exposed to thrombin. Cells were pretreated for 3 h with APC (50 mg/ml) or vehicle (control).
Subsequently, thrombin (50 nM) or medium was added to the cell culture. APC significantly reduced thrombin-induced cell
monolayer permeability, cell stiffening, and cell contraction, measured by electrical impedance, optical magnetic twisting
cytometry, and traction microscopy, respectively, suggesting a barrier-protective response. The dynamics of the barrier
integrity was also assessed by western blotting and immunofluorescence analysis of the tight junction ZO-1. Thrombin
resulted in more elongated ZO-1 aggregates at cell-cell interface areas and induced an increase in ZO-1 membrane protein
content. APC attenuated the length of these ZO-1 aggregates and reduced the ZO-1 membrane protein levels induced by
thrombin. In conclusion, pretreatment with APC reduced the disruption of barrier integrity induced by thrombin, thus
contributing to alveolar epithelial barrier protection.
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Introduction
The pathogenesis of acute lung injury (ALI) and acute
respiratory distress syndrome (ARDS) involves pro-coagulant
and pro-inflammatory mechanisms resulting in disrupted alveolar
epithelium at cell-cell junctions, with the consequent infiltration of
protein-rich edema fluid and inflammatory cells into the alveolar
space [1,2]. Therefore, the physical integrity of the alveolar
epithelial barrier plays an important role in these respiratory
diseases. The integrity of this barrier depends on a dynamic
balance between inward forces–cell mechanical tension generated
by actomyosin contraction and cytoskeleton elastic recoil–and
outward forces exerted by cell-cell and cell-matrix adhesions [3].
During the early stages of ALI/ARDS, pro-inflammatory medi-
ators downregulate the natural anticoagulant pathways and
initiate an increase in pro-coagulant activity [4–6], which could
compromise the force balance in the alveolar epithelium. The
serine protease thrombin is one of the most important pro-
coagulant proteins that increase in the injured lungs of patients
with clinical disorders resulting in ALI/ARDS [7]. Thrombin can
modulate the force balance in alveolar epithelial cells by increasing
cell stiffness [8] and cell contraction [9] and also by enhancing
peripheral remodeling of the actin cytoskeleton [8–10] and of cell-
cell contacts, such as the tight junction ZO-1 [10].
Activated protein C (APC) is an anticoagulant protein that is
formed after the activation of protein C by thrombin-thrombo-
modulin complex on the surface of cells [11], including alveolar
epithelial cells [5]. The endothelial protein C receptor (EPCR)
accelerates protein C activation in a concentration-dependent
manner. In ALI/ARDS patients, the generation of APC in
alveolar compartments could be drastically reduced due to the
lower availability of soluble protein C and the higher fraction of
soluble thrombomodulin in the pulmonary edema fluid of these
patients [5]. Therefore, anticoagulant therapy with inhaled APC
might restore the natural anticoagulant cascades in the alveolar
compartment of ALI/ARDS patients. Recent studies in several
animal models of ALI have found that nebulized administration of
APC attenuates lung injury [12–14] and reduces pulmonary
coagulopathy without systemic anticoagulant effects [15]. Howev-
er, little is known about the mechanisms through which APC
could affect alveolar barrier integrity. APC attenuated thrombin-
induced extracellular-regulated kinase 1/2 (ERK) activation in
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alveolar epithelial cells, a pathway involved in endothelial cell
contraction and barrier dysfunction [16]. Nevertheless, to date, the
direct role of APC in alveolar epithelial cell mechanical tension
and barrier integrity in response to thrombin has not been
investigated.
We aimed to investigate the effects of APC on the stiffening,
contractility, and barrier integrity of human alveolar epithelial
cells subjected to thrombin.
Methods
Reagents and Antibodies
Unless otherwise specified, reagents were obtained from Sigma
(St. Louis, MO, USA). APC (Drotrecogin Alfa [activated]) was
obtained from Eli Lilly and Company (Indianapolis, IN, USA).
Cell Culture
The study was carried out on human lung epithelial cells: A549,
culture line CCL-185; H441, culture line HTB-174 (American
Type Culture Collection; Manassas, VA, USA); and primary
culture of human alveolar epithelial cells (HAECs) isolated from
human lung tissue (Innoprot; Bizkaia, Spain). HAECs comprise
alveolar type I and type II epithelial cells. A549 and H441 cells
were cultured in HEPES-buffered RPMI 1640 medium (GIBCO;
Gaithersburg, MD, USA) supplemented with 10% inactivated
fetal calf serum (GIBCO), 1 mM L-glutamine, penicillin–strepto-
mycin (50 U/ml, 0.05 mg/ml, respectively), and 2.5 mg/ml
amphotericin B. HAECs were propagated in the manufacturer’s
recommended alveolar epithelial cell medium with 2% fetal
bovine serum.
Experimental Protocols
Cells grown to confluence were pretreated with 50 mg/ml APC
(experimental cells) or culture medium (vehicle) for 3 h. Subse-
quently, 50 nM thrombin or culture medium was added to the cell
culture. Cells pretreated with vehicle for 3 h and challenged with
culture medium instead of thrombin were defined as control
group. We conducted preliminary experiments with A549 cells to
determine the dose of APC necessary to reduce thrombin-induced
cell stiffening (0.1 mg/ml, 2.5 mg/ml, 5 mg/ml, or 50 mg/ml) and
to evaluate whether the duration of APC pretreatment (1 h or 3 h)
affected the reduction of cell stiffening (Figure S2).
Cytotoxicity of APC Against A549 Cells
The cytotoxicity of APC, at 0.1 mg/ml, 2.5 mg/ml, 5 mg/ml,
and 50 mg/ml, against A549 cells was evaluated after 72 h of APC
stimulation by MTT Cell Proliferation Assay (R&D systems;
Minneapolis, MN, USA) (Figure S1). This colorimetric assay
measures the activity of cellular enzymes that reduce the
tetrazolium dye, MTT, to its insoluble formazan, reflecting the
cell proliferation rate and conversely, when metabolic events lead
to apoptosis or necrosis, the reduction in cell viability.
Measurement of Monolayer Permeability
The dynamics of barrier function were monitored using a real-
time cell analyzer (RTCA SP) (xCELLigence System, Roche
Applied Science; Mannheim, Germany). This system measures
electrical impedance across the cell monolayer, cell impedance, by
means of gold microelectrodes integrated on the bottom of tissue
culture E-plates (Roche Applied Science; Mannheim, Germany).
The E-Plate 96 has the same layout as conventional 96-well
culture plates, but each individual well on an E-Plate incorporates
a circle-on-line sensor electrode array. Therefore, approximately
80% of the area on the bottom of an E-Plate 96 is covered with
gold microelectrodes. The device station, which is connected with
the E-plate, is placed in the incubator and connected to the
electronic RTCA analyzer through electrical cables. Cell imped-
ance (CI) is a frequency-dependent parameter derived from
impedance change according to CI= (Zi – Z0)/15 V, where Zi is
the impedance at time i (i = 1, 2, …, N) and Z0 is the impedance at
time 0. CI was measured at 10 kHz. When there are no cells in the
wells, Zi =Z0, and therefore CI= 0. A total of 2610
4 A549 cells or
56104 HAECs/H441 cells were cultured in each well. The E-
plate 96 was placed in the incubator for at least 30 min before
starting the experiment to ensure that cells were settled in the
bottom of the well and was then inserted into the device station.
Cell proliferation was assessed for 48 h, at which time the cells
reached a sustained maximum CI value. At this time, cells were
treated in tetraplicate as described above and CI was measured
every minute up to 70 minutes after thrombin challenge. For each
treatment, 7 experiments were carried out. In a series of
experiments, A549 cells were first pretreated with RCR- 252
(20 mg/ml), an EPCR-blocking antibody that inhibits APC
binding, or vehicle (culture medium) for 30 minutes before APC
(50 mg/ml) exposure and 5 minutes of thrombin challenge.
Measurement of Cell Stiffness
Cell stiffness was assessed by optical magnetic twisting
cytometry (OMTC) [17]. Briefly, A549 cells were grown to
confluence and pretreated with APC (50 mg/ml) or culture
medium as described above; 10 mg ferrimagnetic beads coated
with a synthetic RGD (Arg-Gly-Asp) were added to the cell culture
and allowed to bind tightly to the cytoskeleton through cell surface
receptors at 37uC and 5% CO2. Then, the cells were washed with
HEPES-buffered RPMI-1640 to remove unbound beads and the
well was mounted on the OMTC experimental setup. The beads
were permanently magnetized in the horizontal direction
(150 mT, 10 ms) and sinusoidally twisted in the vertical direction
(3 mT, 0.1 Hz). Cell stiffness was measured from the twisting
torque and bead displacement. Thrombin or culture medium was
then added to the cell culture after 1 minute of OMTC baseline
recording, and cell stiffness was measured for 5 additional minutes.
The baseline value of cell stiffness was computed as the average of
data obtained 30s before adding thrombin or culture medium.
Cell stiffness after thrombin challenge was computed as the
average of data obtained between 4.5 and 5 min. This technique
has been described in detail elsewhere [8,18]. For each treatment,
10 wells were tested.
Measurement of Cell Contraction
Cell contraction force was determined using traction microsco-
py (TM), as described elsewhere [9,18]. Briefly, A549 cells were
grown on a thin collagen-coated polyacrylamide gel disk with
embedded fluorescent beads. These flexible substrates were
prepared beforehand using a mixture of 0.2 mm fluorescent latex
beads (Molecular Probes, Invitrogen Corporation; Eugene, OR,
USA) with 2% acrylamide and 0.3% bis-acrylamide solution (Bio-
Rad; Hercules, CA, USA). Gel disks (Young’s modulus, 365 Pa)
prepared with this solution were attached to a coverslip and
subsequently coated with 3 mg/cm2 rat tail collagen I. Twenty-
four hours after plating, cells were pretreated with APC (50 mg/
ml) or culture medium as described above. The sample with the
cell culture was then placed on an inverted microscope (Eclipse TE
2000-E, Nikon; Melville, NY, USA) with a cooled charge-coupled
device camera (Orca AG, Hamamatsu Photonics) to measure cell
contraction. First, a bright field image of an isolated cell was
captured to determine its boundary. Subsequently, the apical
surface of the gel was focused, and a fluorescence image of the
Barrier-Protective Effects of APC in A549 Cells
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beads from the apical surface of the gel was acquired. Thrombin
or culture medium was added to the cell culture and another
fluorescent image was acquired 5 min after the treatment
challenge. At the end of the measurement, cells were removed
from the gel disk by brief exposure to trypsin. Finally, an
additional fluorescent image was recorded to determine the
position of the beads in the unstrained gel (reference image).
The displacement field between each fluorescence image and the
reference image was measured. The traction field was calculated
from Young’s modulus of the gel and the displacement field. For
each traction field, the total force magnitude was computed by
integrating the magnitude of the traction field over the projected
area of the cell. For each treatment, 15 wells were tested.
Protein Extraction and Fractionation
A549 cells seeded in D100 dishes and grown to confluence were
pretreated with 50 mg/ml APC (experimental cells) or culture
medium (vehicle) for 3 h. Subsequently, 50 nM thrombin or
culture medium was added to the cell culture. Five minutes later,
cells were rinsed twice with phosphate-buffered saline (PBS) and
incubated on ice for 30 minutes in the presence of 500 ml of
extraction buffer (20 mM Tris-HCl pH 7.4, 125 mM sucrose,
50 mM NaCl, 2 mM EGTA, 1 mM PMSF, 2 ml protease
inhibitor, and 2 ml phosphatase inhibitor) for lysis. Cells were
scraped and aspirated repeatedly through a 25-gauge needle.
Then, cells were sonicated and ultracentrifuged at 1000006g for
30 minutes, with the cytosolic fraction being the supernatant
product and the membrane/cytoskeleton fraction being the pellet
product. The pellet was resuspended in 100 ml of extraction buffer.
Protein concentration was determined using the bicinchoninic acid
method (Pierce, Thermo Scientific; Rockford, IL, USA).
Western Blot of the ZO-1 Protein
Equal amounts of protein were heat-denatured in sample-
loading buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2%
SDS, 0.1% bromophenol blue, 10% glycerol) resolved in a 6%
SDS-PAGE gel and transferred to PVDF membranes (GE
Healthcare; Buckinghamshire, UK). Next, the blots were blocked
with 5% PBS-non-fat dry milk for 2 hours at room temperature
and then incubated with monoclonal mouse anti–ZO-1 (1.5 mg/
ml) overnight at 4uC. Donkey anti-mouse peroxidase-conjugated
IgG (Jackson Immuno Research; Suffolk, UK) was used as a
secondary antibody, and a-tubulin antibody (Cell Signaling;
Boston, MA, USA) was used as a loading control. Finally, 7
membrane-bound immune complexes were detected by an
enhanced chemiluminescence system (ECL) (GE Healthcare) and
the images were visualized and analyzed using an LAS3000 system
(Fujifilm Life Science; Woodbridge, CT, USA).
Immunofluorescence Microscopy
A549 cells grown to confluence on coverslips were pretreated
with 50 mg/ml APC (experimental cells) or culture medium
(vehicle) for 3 h. Subsequently, 50 nM thrombin or culture
medium was added to the cell culture. Five minutes later, cells
were washed twice with PBS and fixed in 3.7% formaldehyde in
PBS for 10 minutes at room temperature. After three washes with
PBS, cells were permeabilized with a solution of 0.1% Triton X-
100 in PBS for 3 min and stained with Texas-Red C2-maleimide
(Tx-Red) (Molecular Probes, Invitrogen Corporation) diluted
1:100 in PBS for 30 minutes. After three washes with PBS, cells
were blocked with a solution of 2% bovine serum albumin in 0.1%
Tris-buffered saline (TBS)–Tween 20 (TBS-T) (blocking solution)
for 30 minutes and incubated overnight at 4uC with monoclonal
mouse anti-ZO-1 (15 mg/ml) (Zymed laboratories, Invitrogen
Corporation; Carlsbad, CA, USA). The following day, cells were
washed three times with TBS-T, incubated with Alexa 488-
conjugated goat anti-mouse IgG (Molecular Probes, Invitrogen
Corporation) (1:200), and kept in the dark at room temperature for
1 h. After three additional washes with TBS-T, cellular nuclei
were stained with Hoechst 33342 (Molecular Probes, Invitrogen
Corporation) (1:5000) for 5 min at room temperature. Immedi-
ately, coverslips were washed three times with PBS, dried, and
mounted on a microscopy slide with the mounting medium
Mowiol (Calbiochem, Merck; La Jolla, CA, USA). Images were
acquired using a confocal laser scanning microscope (Eclipse TE
2000-E, Nikon; Melville, NY, USA) with a motorized XY stage
MS-2000 (ASI; Eugene, OR, USA) and a 606 oil immersion
objective; images were processed with MetaMorph 7.1 Software
(Molecular Devices; Sunnyvale, CA, USA) to analyze the length of
tight junction ZO-1 aggregates. A total of 27 images per treatment
were used to quantify the ZO-1 length between cells.
Statistical Analysis
Data are reported as mean 6 SE. Comparisons between results
obtained from different experiments were carried out by one-way
ANOVA followed by the post-hoc Student-Newman-Keuls test,
with the exception of APC dose-response and time-dependence
results, which were assessed by unpaired Student’s t-test. When
data failed the normality test in the one-way ANOVA, the
Kruskal–Wallis one-way ANOVA on ranks was used. Statistical
significance was set at p,0.05.
Results
Changes in Human Lung Epithelial Permeability Induced
by Thrombin and APC
The acute response to thrombin produced a significant decline
in CI in all three cell types: 12.6% in A549 (Figure 1A), 13.5% in
HAECs (Figure 1B), and 5.8% in H441 (Figure 1C), reflecting
increased permeability. This decline in CI was rapid, reaching a
low point between 1 and 10 minutes after thrombin challenge.
Thereafter, the pattern of the response to thrombin in the three
human lung epithelial cell types differed. In A549 cells, CI
increased rapidly for 20 minutes after reaching the low point and
remained high for up to 70 minutes. In HAECs, CI increased
slowly and progressively. In H441 cells, CI immediately returned
to baseline values but remained lower in comparison to the control
group throughout the 70 minutes. The thrombin-induced acute
decline in CI was significantly attenuated by pretreatment with
APC in all three human lung epithelial cell types (4.6% in A549
cells, 5.9% in HAECs, and 1.4% in H441 cells). This indicates that
APC prevents the thrombin-induced increase in human lung
epithelial permeability. No significant differences in CI values were
found between cells pretreated with APC alone and control cells.
As the acute response to thrombin showed similar behavior in
all three human lung epithelial cells, all further experiments were
carried out in A549 cells and at 5 minutes.
Effect of APC on Mechanical Tension of A549 Monolayers
Exposed to Thrombin
Figure 2 shows that thrombin induced a 2.5-fold increase in cell
stiffness (vs. baseline data); pretreatment with APC significantly
attenuated the increase to 1.5-fold. Thrombin induced a 2.5-fold
increase in cell contraction (total force vs. baseline data);
pretreatment with APC significantly attenuated the increase to
2.0-fold. No significant changes were found between APC-
pretreated and control cells in either measurement of cell
mechanics.
Barrier-Protective Effects of APC in A549 Cells
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Role of ZO-1 in APC- and Thrombin-mediated Dynamics
of Alveolar Epithelial Barrier Integrity
Cytosolic and membrane/cytoskeletal fractions were isolated
from A549 cells and subjected to western blotting using ZO-1
antibody. Thrombin induced a 4.4-fold increase in ZO-1
membrane protein levels (percentage compared to control group)
(Figure 3) that was significantly reduced (p,0.05) to a 2.1-fold
increase when cells were pretreated with APC. Pretreatment with
APC alone did not significantly modify the membrane protein
levels compared to the control group. In addition, no statistically
significant differences were observed in the cytosolic fraction in
any of the conditions evaluated.
On immunofluorescence images, we limited the observation of
ZO-1 to the areas where cells were in contact, because A549 cells
are unable to create a tight monolayer (Figure 4A). In control
conditions, ZO-1 appeared as discontinuous aggregates at cell-cell
contacts, and the appearance of ZO-1 staining in cells pretreated
with APC was similar. When cells were challenged with thrombin
(50 nM), these ZO-1 aggregates become more elongated and
assembled perpendicular to cell-cell interface areas (Figure 4,
arrows). These elongated aggregates induced by thrombin seemed
to be attenuated in cells pretreated with APC. The length of this
tight junction was quantified using immunofluorescent images
(Figure 4B). Thrombin induced a 3.1-fold increase in ZO-1
aggregate length (relative to the control group); pretreatment with
APC for 3 h significantly reduced the thrombin-induced increase
in ZO-1 aggregate length to 1.9-fold.
Discussion
In the present study, we measured the effect of APC on cell
stiffness, cell contraction, and cell barrier integrity in human
alveolar epithelial cells subjected to thrombin. The collective
findings show that APC pretreatment significantly reduced the
effects of thrombin on cell mechanics and cell barrier integrity in
the A549 monolayer, suggesting a barrier-protective response.
The structural integrity of the alveolar epithelial monolayer is
regulated by the balance between inward tension forces and
outward adhesive tethering forces at cell-cell and cell-matrix
contacts. In this simple model, paracellular gaps form and the
barrier is disrupted when adhesive cell-cell and cell-matrix
tethering forces that regulate cell shape are unable to withstand
cell tension forces exerted by cytoskeleton viscoelastic recoil and
contraction of the actomyosin machinery [3]. In particular,
thrombin can modulate this force balance [8–10,18], acting near
the site of its generation [19] through protease-activated receptors
(PAR-1, PAR-3, and PAR-4).
We found that thrombin increased permeability in human lung
epithelial cells (Figure 1) during the acute response. Although the
establishment of functional tight junctions and the formation of
impermeable monolayers by A549 cells has been questioned
[20,21], the acute thrombin response in A549 cell permeability
was similar to that of HAECs composed of alveolar type I and type
II epithelial cells and of H441 cells, a respiratory epithelial cell line
that is able to form confluent monolayers. Based on these findings
Figure 1. Effect of APC pretreatment on cell permeability of
human lung epithelial monolayers exposed to thrombin.
Cellular impedance (CI) was measured through electrical impedance
across the human lung epithelial monolayers. At the time that confluent
human lung adenocarcinoma cell lines A549 (A) and H441(C) and
primary culture of human alveolar epithelial cells (HAECs) (B) reached a
sustained maximum CI value, cells were pretreated with APC (50 mg/ml)
or culture medium (vehicle) for three hours. Subsequently, thrombin
(50 nM) or culture medium was added to the wells and CI was
measured every minute up to 70 minutes after thrombin challenge.
Black circles represent control cells (pretreated with vehicle for 3 h and
then challenged with culture medium); white circles represent cells
pretreated with vehicle and exposed to thrombin (50 nM); black
triangles represent cells pretreated with APC (50 mg/ml) and challenged
with culture medium; and white triangles represent cells pretreated
with APC (50 mg/ml) and exposed to thrombin (50 nM). Data are
reported as mean 6 SEM. * and # denote significant differences
between the vehicle + thrombin and APC + thrombin groups and
between the vehicle + thrombin and control groups, respectively.
Statistical significance was set at P,0.05. Measurements of monolayer
permeability were performed on seven wells for each condition.
doi:10.1371/journal.pone.0056965.g001
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and the fact that A549 cells can also express different proteins
involved in the coagulation cascade [5,22,23] and can generate
new APC in the presence of thrombin and protein C antigen [24],
we considered the A549 cell line an appropriate model to study the
effects of APC on the structural integrity of the alveolar epithelial
monolayer subjected to thrombin. Moreover, the acute thrombin
response found in A549 cell permeability is in line with several
data showing that thrombin induces a more marked effect after
five minutes of treatment [8,10,14,18]. In agreement with previous
studies, we found that thrombin stiffens and contracts alveolar
epithelial cells, suggesting an increase in inward forces compro-
mising the barrier integrity [8,9,18]. In this study, we found that
the thrombin-induced increase in cell stiffness and contraction is
associated with a significant increase in cell permeability. Although
some evidence suggests that thrombin compromises barrier
integrity, other evidence suggests that thrombin can enhance cell
adhesion in A549 cells, which could reinforce barrier integrity. In
particular, thrombin induces the formation of actin bundles [8–10]
and accumulation of MLC diphosphorylation in the peripheral
ring [10]; and as previously reported [10], we also found cell
membrane recruitment of the tight junction protein ZO-1.
The apparent divergence in the role of thrombin in alveolar
epithelial cells could be explained by cell intrinsic mechanisms
preserving the cell barrier integrity in response to an increase in
centripetal tension. Recent data demonstrate that under the
application of a local cell force, such as cell contraction inducing
paracellular permeability, more adhesive proteins are recruited to
the affected contacts to reinforce them [25,26]. Previous studies
reported that ZO-1 protein undergoes posttranslational modifica-
tions induced by different stimuli, such as phosphorylation [27,28].
As many proteins belonging to the tight junctional complex,
including ZO-1, are phosphoproteins [27], the rapid enhancement
of these proteins in the cell membrane compartment is a
consequence of changes in their phosphorylation state [28]. In
fact, these phosphorylated changes are associated with tight
junction functions and in particular with paracellular permeability
[27–29]. Considering that thrombin induced an increase in A549
cell permeability, the thrombin-induced increase of ZO-1 protein
levels in the membrane compartment could be the result of a
posttranslational modification such as phosphorylation. However,
further studies are needed to elucidate this mechanism. Moreover,
on immunofluorescence images, the thrombin-induced elongated
ZO-1 aggregates were situated perpendicularly in the areas where
cells are in contact. This ZO-1 pattern was also observed in
human pulmonary artery endothelial cells treated with thrombin
[10] and is also very similar to that induced by some cadherins in
different cell types [10,30–32]. Brevier and coworkers [30]
recently correlated the formation and length of the adherens
junction VE cadherin with cell contractility. The larger the
contractile force, the greater the length of the cell-cell junction
aggregates formed between adjacent cells [30]. Under this
hypothesis, the cell-cell contact needs to be linked to the actin-
myosin apparatus; ZO-1 is connected directly to the perijunctional
actin ring [33] and interacts with myosin through cingulin, a
cytoplasmatic protein belonging to the tight junctional complex
[34]. Considering the similarity of the pattern observed in
adherens junctions in response to contractile agents to those
observed in tight junctions, cell contraction could affect the length
of the tight junction ZO-1. This interpretation is supported by our
finding that the length of ZO-1 aggregates at cell-cell contacts for
all cell treatments showed a linear dependence with the
corresponding total force magnitude (Figure S3).
Figure 2. Effect of APC pretreatment (50 mg/ml) on cell mechanics in response to thrombin. Confluent A549 cells were pretreated with
APC (experimental cells) or culture medium (vehicle cells). Cell stiffness and normalized total force magnitude was measured before (baseline
recording) and 5 minutes after thrombin or culture medium challenge. Values are normalized to baseline values and reported as mean 6 SEM. The
statistical significance of the results was assessed by one-way ANOVA. * and # indicate significant differences between the vehicle + thrombin and
APC + thrombin groups and between the vehicle + thrombin and control groups, respectively (p,0.05).
doi:10.1371/journal.pone.0056965.g002
Barrier-Protective Effects of APC in A549 Cells
PLOS ONE | www.plosone.org 5 February 2013 | Volume 8 | Issue 2 | e56965
The anti-inflammatory effects of APC at the endothelial level
have been widely studied [35–38]. By contrast, the role of APC in
the alveolar epithelium is poorly understood. We found no
significant differences in cell stiffness between APC-pretreated
alveolar epithelial cells and control cells, at any of the four doses
studied (data not shown). Moreover, no significant changes in cell
permeability were found between any of the three human lung
epithelial cells pretreated with APC and control cells. Likewise, no
significant changes in cell contraction or in the dynamics of ZO-1
were found between A549 cells pretreated with APC and control
cells. These results suggest that APC alone does not mediate
mechanical or biological responses that may compromise the
integrity of the alveolar epithelial barrier. This finding is in line
with recent data showing that APC induces a minimal response on
the phosphorylation of ERK1/2 [14], a mitogen-activated protein
kinase involved in endothelial cell permeability [16]. On the other
hand, we found that APC reduced thrombin-induced responses in
human lung epithelial cells, as occurs in the endothelium. Maniatis
and colleagues recently found that APC attenuates the activation
of ERK1/2 induced by thrombin in alveolar epithelial cells [14],
suggesting that APC could reduce the stress fiber formation and
cell permeability induced by thrombin in the alveolar epithelium,
as occurs in the endothelium [16]. However, to date, the direct
role of APC in reducing thrombin-induced cell contraction, cell
stiffness, and cell permeability in alveolar epithelial cells has not
been reported.
Pretreatment with APC not only significantly reduced throm-
bin-induced A549 cell stiffening, cell contraction, and cell
permeability, but also decreased the levels of ZO-1 in the
membrane protein content and the number of elongated ZO-1
aggregates that were assembled perpendicular to cell-cell interface
areas. APC also reduced thrombin-induced cell permeability in
Figure 3. Recruitment of the tight junction protein ZO-1 at cell membrane after APC and thrombin exposure. Levels of ZO-1 protein in
the membrane/cytoskeleton and cytosolic fractions were evaluated by western blot. A549 cells were pretreated with APC at 50 mg/ml or vehicle for
3 h, followed by thrombin (50 nM) or culture medium treatment for 5 min. Tubulin was used as an invariant control. Data from seven independent
experiments are reported as mean values 6 SEM. The results are expressed as a percentage of control (vehicle + culture medium group). The
statistical significance of the results was assessed by one-way ANOVA (p= 0.038). * and # indicate significant differences between the vehicle +
thrombin and APC + thrombin groups and between the vehicle + thrombin and control groups, respectively (p,0.05).
doi:10.1371/journal.pone.0056965.g003
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HAECs and in H441 cells, with a significant difference achieved in
HAECs during the first 5 minutes of thrombin challenge.
Taken together, these results suggest that when inward forces
increase in response to a contractile stimulus, such as thrombin, a
protective intrinsic cell mechanism to preserve barrier integrity is
also activated. However, when this contractile stimulus is
minimized, such by the action of APC, the protective intrinsic
cell mechanism in response to centripetal tension may not be
entirely necessary. Therefore, the barrier-protective response to a
contractile stimulus could depend on the strength of this stimulus.
One of the mechanisms by which APC mediates the barrier
protective response in endothelial cells is cleaving and activating
PAR-1 in an EPCR-dependent fashion [35]. As A549 cells can
express EPCR [22], we sought to evaluate the role of this receptor
in APC-preserved barrier integrity in response to thrombin. We
found no significant differences in CI between the cells pretreated
with an EPCR-blocking antibody that inhibits APC binding and
vehicle cells (Figure S4). These results indicate that APC is able to
reduce thrombin-induced responses in alveolar epithelial cells
without binding to EPCR, suggesting that other mechanisms could
be involved. Further studies are needed to elucidate these
complementary mechanisms.
In conclusion, our results demonstrate that pretreatment with
APC significantly reduces the effects of thrombin in alveolar
epithelial cells, suggesting a barrier-protective response. We
hypothesize that, as a consequence of thrombin-induced increases
in inward forces, outward tethering adhesive forces were also
reinforced through a protective intrinsic cell mechanism to preserve
barrier integrity, such as ZO-1 recruitment at the cell membrane.
This reinforcement could be minimized by the protective effects of
APC. Further research using other stimuli will help us to better
understand the dynamics of mechanical forces at cell-cell attach-
ments and the role of different tight junctions on alveolar-capillary
barrier disruption in in vitro models of ALI. Overall, our findings
provide new insights into the protective effects of APC on the
alveolar epithelial barrier by restoring the coagulation pathways in
the alveolar space of ALI patients.
Supporting Information
Figure S1 Viability of A549 cells treated with APC at
four different concentrations. Cell viability was assessed at
four different concentrations (0.1 mg/ml, 2.5 mg/ml, 5 mg/ml, and
50 mg/ml) for 72 h by MTT assay. According to the manufac-
turer’s instructions, an APC dose may be cytotoxic for A549 cells
when cell viability is less than 80%. Values are reported as mean
6 SEM. APC dose-response and time-dependence results.
(TIF)
Figure 4. Effect of APC pretreatment (50 mg/ml) on tight junction ZO-1 integrity after thrombin challenge. The location and length of
the tight junction ZO-1 in alveolar epithelial cells was assessed by immunofluorescence. A549 cells were pretreated with APC at 50 mg/ml or vehicle
for 3 h. Subsequently, thrombin or culture medium was added to the cell culture for 5 min. In Figure A, ZO-1 fluorescence is indicated by green and
Texas-red maleimide staining, which shows cell membranes, in red. Arrows show elongated aggregates of ZO-1 at cell-cell contacts. Representative
results of 3 independent experiments. Scale bar = 10 mm. Figure B shows the quantification of ZO-1 length at cell-cell contacts of A549 cells; 27
images per treatment were used to quantify the ZO-1 length between cells. Results are reported as mean 6 SEM. * and # denote significant
differences between the vehicle + thrombin and APC + thrombin groups and between the vehicle + thrombin and control groups, respectively
(p,0.05).
doi:10.1371/journal.pone.0056965.g004
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Figure S2 APC dose-response and time-dependence on
cell stiffness in response to thrombin. Cell stiffness was
measured by optical magnetic twisting cytometry (OMTC).
Confluent A549 cells were pretreated with APC at different
conditions or vehicle. Thrombin (50 nM) or culture medium was
added to the wells after OMTC baseline recording, and 5 minutes
later cell stiffness was measured. (A) Cells were pre-treated with
APC at four different concentrations (0.1, 2.5, 5, and 50 mg/ml) or
vehicle (culture medium) for 1 hour. (B) A549 cells were pre-
treated with the highest APC concentration (50 mg/ml), close bars,
or vehicle, open bars, for 1 or 3 hours. Data are reported as mean
6 SEM (***, **, and * indicate P,0.001, P,0.01, and P,0.05,
respectively). OMTC measurements were performed on nine wells
for each condition.
(TIF)
Figure S3 Relationship between the length of ZO-1
aggregates at cell-cell contacts and the traction forces.
The median ZO-1 aggregate length for each group is plotted
versus the median total force magnitude in the same conditions.
Black circles represent control cells (pretreated with vehicle for 3 h
and afterwards challenged with culture medium), white circles
represent cells pretreated with vehicle and exposed to thrombin
(50 nM), black triangles represent cells pretreated with APC
(50 mg/ml) and challenged with culture medium, and white
triangles represent cells pretreated with APC (50 mg/ml) and
exposed to thrombin (50 nM). The line resulting from a linear fit
of the data has a slope obtained of 0.6398 with R2= 0.967.
(TIF)
Figure S4 Role of EPCR in APC-mediated barrier-
protective response. Cells were first pretreated with RCR-
252 (20 mg/ml), an EPCR-blocking antibody that inhibits APC
binding, or vehicle (culture medium) for 30 minutes before
exposure to APC (50 mg/ml). After three hours, cells were
challenged with thrombin (50 nM), and 5 minutes later cell
impedance was measured. Cells were treated in tetraplicate. For
each treatment, 6 experiments were carried out. Data are reported
as mean 6 SEM.
(TIF)
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